Association of Concomitant Amlodipine Use With Serum Olanzapine Concentrations and Clinical Outcomes in Patients With Schizophrenia
Human Psychopharmacology: Clinical and Experimental · 2026
DOI: 10.1002/hup.70062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, 2026. Verfasst von Xiaoxiao Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Amlodipine, Schizophrenia, Antipsychotic Agents, Antihypertensive Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan,430065, China.
Abstract (Originalsprache)
Objective
To examine whether concomitant amlodipine use was associated with steady‐state serum olanzapine concentration and clinical outcomes in patients with schizophrenia.
Methods
This retrospective study included 45 inpatients with schizophrenia and hypertension who received olanzapine 10 mg/day plus amlodipine 5 mg/day (experimental group) and 52 inpatients who received olanzapine 10 mg/day alone (control group). PANSS and SDSS scores were assessed at baseline and week 7, and recorded adverse events were evaluated at week 9.
Results
Mean serum olanzapine concentration was lower in the combination group than in the olanzapine‐alone group (40.56 ± 18.86 vs. 50.23 ± 23.41 ng/mL; unadjusted p = 0.027; age‐adjusted p = 0.032) (Figure 1). Improvements in positive symptoms, negative symptoms, and SDSS scores were smaller in the combination group, whereas PANSS total and general psychopathology changes did not differ. Serum olanzapine concentration was not significantly correlated with any PANSS or SDSS change. Recorded adverse‐event rates did not differ significantly.
Conclusions
Concomitant amlodipine use was associated with lower serum olanzapine concentration and smaller improvements in selected clinical domains. The individual‐level analyses did not establish a concentration‐response relationship, and the retrospective design precludes causal inference. Haemodynamic safety could not be evaluated because complete standardised blood‐pressure data were unavailable. These findings suggest that closer monitoring of clinical response and serum olanzapine concentrations may be considered when amlodipine is co‐prescribed, particularly in patients with suboptimal treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
- Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China.
- Department of Clinical Laboratory, Third Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
ORCID-Profile: Xiaoxiao Chen
Förderung
- Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan,430065, China
Zitieren
APA
Chen, X., Ma, J., Xuan, X., Huang, M., Yang, X., & Huang, B. (2026). Association of Concomitant Amlodipine Use With Serum Olanzapine Concentrations and Clinical Outcomes in Patients With Schizophrenia. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.70062
Vancouver
Chen X, Ma J, Xuan X, Huang M, Yang X, Huang B. Association of Concomitant Amlodipine Use With Serum Olanzapine Concentrations and Clinical Outcomes in Patients With Schizophrenia. Human Psychopharmacology: Clinical and Experimental. 2026. doi:10.1002/hup.70062
BibTeX
@article{Chen2026,
author = {Chen, Xiaoxiao and Ma, Jing and Xuan, Xiaolei and Huang, Mao and Yang, Xue and Huang, Baorong},
title = {Association of Concomitant Amlodipine Use With Serum Olanzapine Concentrations and Clinical Outcomes in Patients With Schizophrenia},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2026},
doi = {10.1002/hup.70062}
}
EUVIMED